Literature DB >> 2171685

Cortical concentrations of corticotropin-releasing hormone and its receptor in Alzheimer type dementia and major depression.

A Leake1, E K Perry, R H Perry, A F Fairbairn, I N Ferrier.   

Abstract

Corticotropin-releasing hormone-immunoreactivity (CRH-IR) and CRH receptors (binding capacity and affinity) were measured in postmortem cortical areas from depressed subjects, two groups of senile dementia of the Alzheimer type (SDAT), and age-, sex-, and postmortem-delay-matched controls. No difference in CRH-IR and CRH receptor status between depressed subjects and controls was noted. CRH-IR was decreased in all cortical areas in SDAT, with a corresponding increase in CRH receptor binding capacity (with no change in affinity) in occipital cortex. No effects of postmortem delay were seen. It is suggested that the increase in CRH receptor numbers in SDAT is related to the degree of distribution of pathological involvement in specific regions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171685     DOI: 10.1016/0006-3223(90)90398-l

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

Review 1.  Role of corticotropin releasing factor in anxiety disorders: a translational research perspective.

Authors:  Victoria B Risbrough; Murray B Stein
Journal:  Horm Behav       Date:  2006-07-25       Impact factor: 3.587

Review 2.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

Review 3.  Sex-biased stress signaling: the corticotropin-releasing factor receptor as a model.

Authors:  Rita J Valentino; Debra Bangasser; Elisabeth J Van Bockstaele
Journal:  Mol Pharmacol       Date:  2012-12-13       Impact factor: 4.436

Review 4.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

Review 5.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

6.  Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1.

Authors:  Mark O Huising; Joan M Vaughan; Shaili H Shah; Katherine L Grillot; Cynthia J Donaldson; Jean Rivier; Gert Flik; Wylie W Vale
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

7.  Corticotropin-releasing hormone (CRH) downregulates the function of its receptor (CRF1) and induces CRF1 expression in hippocampal and cortical regions of the immature rat brain.

Authors:  Kristen L Brunson; Dimitri E Grigoriadis; Marge T Lorang; Tallie Z Baram
Journal:  Exp Neurol       Date:  2002-07       Impact factor: 5.330

8.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

9.  Corticotropin-releasing factor overexpression gives rise to sex differences in Alzheimer's disease-related signaling.

Authors:  D A Bangasser; H Dong; J Carroll; Z Plona; H Ding; L Rodriguez; C McKennan; J G Csernansky; S H Seeholzer; R J Valentino
Journal:  Mol Psychiatry       Date:  2016-10-18       Impact factor: 15.992

10.  Melatonin suppresses chronic restraint stress-mediated metastasis of epithelial ovarian cancer via NE/AKT/β-catenin/SLUG axis.

Authors:  Shixia Bu; Qian Wang; Junyan Sun; Xiao Li; Tingting Gu; Dongmei Lai
Journal:  Cell Death Dis       Date:  2020-08-18       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.